Quotient Therapeutics continued to draw major pharma partnerships for its somatic genomics platform, this time with Merck focused on inflammatory bowel disease (IBD). Merck will pay Quotient $20 million upfront for a multi-year research collaboration to identify genetic clues and novel drug targets in IBD, with total potential consideration described as more than $2.2 billion including development, regulatory, and commercial milestones. Merck Research Laboratories emphasized that immunology is a key discovery focus. Quotient’s platform uses nanobrate genome sequencing to identify somatic mutations in disease-driving cells, and pairs the findings with AI to propose druggable targets. It has previously signed similar work with Pfizer and GSK in other therapeutic areas. For IBD drug discovery, the deal is another signal that somatic mutation mapping is moving from early translational concept toward broad clinical pipeline input for major sponsors.